"Promising New Drug Shrinks Pancreatic Tumors by 70% in Preclinical Model"

An experimental drug has shown promising results in shrinking pancreatic tumors by up to 70% in lab studies, offering hope for a more effective treatment for the aggressive and deadly cancer. The drug targets genetic drivers of pancreatic ductal adenocarcinomas, with researchers observing tumor shrinkage in 7 out of 10 models. This breakthrough comes as pancreatic cancer, which affects 67,000 Americans annually, has a low survival rate and is often diagnosed at late stages. Clinical trials will be crucial in determining the drug's potential to change the standard of care for pancreatic cancer patients.